Scott Barclay

Scott Barclay leads Point72 Ventures investment activities in healthcare related technologies, with a mission to back ambitious founders leveraging technology and empathy to rebuild healthcare.

Barclay has deep expertise in healthcare and the commercialization and scale of deep tech. Prior to joining Point72 Ventures, Scott was a Partner at DCVC, where he led the Computational Care investment thesis that was focused on backing companies pushing deep compute into healthcare. He invested in and served on the boards of numerous DCVC portfolio companies, including Carbon Health and Medical Informatics Corp. Prior to joining DCVC, he invested and advised broadly in new digital healthcare concepts, helped create and served as Chief Strategy and Product Officer of Surescripts, and led operational and innovation teams across CVS Health.

Previously, Scott worked at The Boston Consulting Group, helped establish a capital markets desk in London for Bank of America Securities, and worked on a manufacturing floor in his hometown in Virginia.

Scott earned his B.A. in History from the University of Virginia and his M.B.A from INSEAD in Fontainebleu, France. 

Marta Andres-Terre

Marta Andres-Terre, PhD is a member of the Healthcare investment team at Point72 Ventures, responsible for diligence and investing in early-stage companies at the forefront of the field of computational care.

Prior to joining Point72, Marta was a consultant at Bain and Company in San Francisco, where she mainly worked on their technology and healthcare practices.

Marta graduated Summa Cum Laude with a B.S. in Biomedical Sciences from the University of Barcelona and a PhD in Immunology from Stanford University. While at Stanford she worked in the Biomedical Informatics and Microbiology departments investigating the immune response to infection, using experimental tools, as well as computational and data science (AI/ML) methods. She was also the president of Stanford’s Biotechnology club.